STAA:NSD-STAAR Surgical Company (USD)

EQUITY | Medical Instruments & Supplies | NASDAQ Global Market

Last Closing

USD 32.37

Change

-0.32 (-0.98)%

Market Cap

USD 0.43B

Volume

0.45M

Analyst Target

USD 64.60
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Staar Surgical along with its subsidiaries designs, develops, manufactures and sells implantable lenses and delivery systems for the eye. The Company develops, produces, and markets intraocular lenses.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-27 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

+3.08 (+0.63%)

USD 171.18B
COO The Cooper Companies, Inc. Com..

+0.35 (+0.32%)

USD 21.23B
HOLX Hologic Inc

+0.41 (+0.51%)

USD 19.09B
ALGN Align Technology Inc

+3.71 (+1.65%)

USD 17.10B
RGEN Repligen Corporation

-1.47 (-1.03%)

USD 8.09B
MMSI Merit Medical Systems Inc

-1.17 (-1.20%)

USD 5.60B
XRAY Dentsply Sirona Inc

+0.66 (+2.67%)

USD 5.18B
ICUI ICU Medical Inc

+3.76 (+2.21%)

USD 3.96B
AZTA Azenta Inc

+0.83 (+1.80%)

USD 2.25B
LMAT LeMaitre Vascular Inc

+1.43 (+1.65%)

USD 1.99B

ETFs Containing STAA

XSU:CA iShares US Small Cap (CAD.. 0.00 % 0.36 %

+0.49 (+1.21%)

CAD 0.69B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.72% 67% D+ 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.72% 67% D+ 54% F
Trailing 12 Months  
Capital Gain -27.91% 42% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.91% 41% F 29% F
Trailing 5 Years  
Capital Gain 7.15% 56% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.15% 57% F 46% F
Average Annual (5 Year Horizon)  
Capital Gain 27.96% 82% B 83% B
Dividend Return 27.96% 82% B 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 95.42% 18% F 18% F
Risk Adjusted Return 29.31% 69% C- 63% D
Market Capitalization 0.43B 74% C 76% C+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 102.16 21% 11%
Price/Book Ratio 3.93 33% 28%
Price / Cash Flow Ratio 112.13 10% 2%
Price/Free Cash Flow Ratio 44.55 13% 7%
Management Effectiveness  
Return on Equity 4.36% 71% 65%
Return on Invested Capital 4.38% 71% 66%
Return on Assets 3.67% 76% 81%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.